The Swedish National Board of Health and Welfare has published a preliminary version of National guidelines for endometriosis care

Apr 2018

On the 22nd of March, 2018, the National Board of Health and Welfare (Socialtyrelsen) has published a preliminary version of National guidelines for endometriosis care. This document provides the recommendations for early diagnostic, pharmacological, non-pharmacological and surgical treatment, pregnancy-related pain relief, follow-up and the importance of the involvement of multi professional health care team in a treatment process. As the National guidelines are published in a format of preliminary version, the National Board of Health and Welfare (Socialtyrelsen) is opened for comments and suggestions until the 31st of May, 2018.

See full details in Swedish here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

MTP Council updated recommendations on gene expression analysis for decision-making on the adjuvant breast cancer treatment

Mar 2022

In late January 2022, Swedish Medical Technologies Product (MTP) Council issued an updated version of recommendations regarding gene expression analysis for decision-making on the adjuvant breast cancer treatment, initially published in November 2021. The recommendation to the regions remains the same. The changes were only concerned with the clarification of some facts.

Swedish MTP Council updated the recommendations on FreeStyle Libre

Mar 2022

In February 2022, Swedish Medical Technologies Product (MTP) Council issued an updated recommendation on FreeStyle Libre for continuous glucose monitoring in type 2 diabetes (T2D). The initial recommendations were published by NT Council in 2018 and updated by MTP Council in 2020 to include FreeStyle Libre 2. In the 2022 update, MTP Council decreased the Hba1c limit from 70 to 60 mmol/mol and added a statement on lifestyle changes and treatment optimization with non-insulin antidiabetic drugs.

Assessments of monitoring and diagnostics of atrial fibrillation products released in Sweden

Mar 2022

On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.

Theme survey on products for monitoring and diagnostics of sepsis launched by Swedish TLV

Mar 2022

At the end of February 2022, the Dental and Pharmaceutical Benefits Agency (TLV) has launched a theme survey on products for monitoring and diagnostics of sepsis to identify products that may be relevant for health economic assessments at TLV. The suggestions for the products of interest, ongoing clinical studies, or innovation projects could be received until 23 March 2022.

Theme survey for obstructive pulmonary diseases completed by Swedish TLV

Jan 2022

In December 2021, the Swedish Dental and Pharmaceutical Benefits Agency (TLV) finished the theme survey in the obstructive pulmonary diseases field, which was conducted as a part of the Orderly Introduction for Medical Technologies framework. Identified technologies could potentially be included in the Orderly Introduction of Medical Technologies framework, which aims to facilitate the introduction of novel technologies on the national level.